Filed Under News 

Drug May Reverse Huntington’s Disease Symptoms



Huntington’s disease (HD) afflicts approximately 30,000 Americans, whose symptoms include uncontrolled movements and progressive cognitive and psychiatric problems. The disease is caused by the mutation of a single gene, which results in the production and accumulation of toxic proteins throughout the brain. Currently, there is no effective treatment.


According to an article published online in the journal Neuron (12 June 2012), with a single drug treatment, researchers at the Ludwig Institute for Cancer Research at the University of California, San Diego School of Medicine have silenced the mutated gene responsible for HD, slowing and partially reversing progression of the fatal neurodegenerative disorder in animal models. The authors suggested that the drug therapy, tested in mouse and non-human primate models, could produce sustained motor and neurological benefits in human adults with moderate and severe forms of the HD.


For the study, mouse and primate models of HD were infused with one-time injections of an identified DNA drug based on antisense oligonucleotides (ASOs). These ASOs selectively bind to and destroy the mutant gene’s molecular instructions for making the toxic huntingtin protein. The singular treatment produced rapid results. Treated animals began moving better within one month and achieved normal motor function within two. More remarkably, the benefits persisted, lasting nine months, well after the drug had disappeared and production of the toxic proteins had resumed.


According to the authors, for diseases like HD, where a mutant protein product is tolerated for decades prior to disease onset, these findings open up the provocative possibility that transient treatment can lead to a prolonged benefit to patients, and that the finding raises the prospect of a ‘huntingtin holiday,’ which may allow for clearance of disease-causing species that might take weeks or months to re-form. If so, then a single application of a drug to reduce expression of a target gene could ‘reset the disease clock,’ thus providing a benefit long after huntingtin suppression has ended.


Beyond improving motor and cognitive function, the authors said the ASO treatment also blocked brain atrophy and increased lifespan in mouse models with a severe form of the disease. The therapy was equally effective whether one or both huntingtin genes were mutated, a positive indicator for human therapy.


The authors noted that the approach was particularly promising because antisense therapies have already been proven safe in clinical trials and are the focus of much drug development. Moreover, the findings may have broader implications for other “age-dependent neurodegenerative diseases that develop from exposure to a mutant protein product” and perhaps for nervous system cancers, such as glioblastomas.


Leave a Reply

You must be logged in to post a comment.